Search - tctmd.com

Displaying 61 - 80 of 110

Sort: Relevancy | Date

Presentation TCT 2014

Detection of Paclitaxel Contamination Resulting from the Simulated Clinical Use of Drug Coated Balloon Catheters

Presenter: Charisse Ward

September 16, 2014

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

Presentation TCT 2014

TCT 267: Lower Mortality of Paclitaxel-Coated Balloon Compared with Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis: Two-Year Follow-up of the PEPCAD China ISR Trial

Presenter: Run-Lin Gao, Jochen Wöhrle, Bruno Scheller, Yelin Zhao

September 13, 2014

News Conference News TCT 2014

PEPCAD-DES at 3 Years: Paclitaxel-Coated Balloon Holds Advantage for DES Restenosis

September 13, 2014

News Conference News TCT 2013

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

November 03, 2013

Presentation TCT 2013

Vascular Healing in the Setting of Drug Deposition via Paclitaxel-Coated Balloon Delivery: Biological Implications for Device Development

Presenter: Michael Joner

October 31, 2013

News Conference News TCT 2013

Drug-coated Balloons May Become Standard of Care in ISR

October 31, 2013

Presentation TCT 2013

LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries

Presenter: Kenneth Rosenfield

October 30, 2013

Presentation TCT 2013

RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

Presenter: Fernando Alfonso

October 30, 2013

News Conference News TCT 2013

LEVANT 2, RIBS Show Promise for Paclitaxel-Coated Balloons in PAD and CAD

October 30, 2013

Presentation TCT 2013

TCT-38. Three-year clinical data of the BIOSOLVE-I Study with the paclitaxel-eluting bioabsorbable magnesium scaffold (DREAMS) and multi-modality imaging analysis

Presenter: Michael Haude

October 29, 2013

Presentation TCT 2013

TCT-13. Final Five Year Results From The All-comer COMPARE Trial: A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

Presenter: Peter Smits

October 29, 2013

Presentation TCT 2013

TCT-56. PEPCAD China ISR: A Prospective, Multicenter, Randomized Trial of Paclitaxel-Coated Balloon versus Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis ...

Presenter: Bo Xu

October 29, 2013

Presentation TCT 2013

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Presenter: David Cohen

October 28, 2013

Presentation TCT 2013

PATENT-C: A Prospective, Randomized Trial of a Paclitaxel-Coated Scoring Balloon vs. a Standard Balloon for Treatment of Coronary In-Stent Restenosis

Presenter: Bruno Scheller

October 28, 2013

Presentation TCT 2013

A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon Plus Bare Metal Stents vs. Paclitaxel-Eluting Stents for De Novo Coronary Lesions

Presenter: Piotr Buszman

October 28, 2013

Presentation TCT 2013

Update on the DREAMS Paclitaxel-eluting and Sirolimus-eluting Magnesium Scaffolds: Device Design, Elution Kinetics, Imaging and Extended Clinical Results

Presenter: Michael Haude

October 27, 2013

Presentation TCT 2013

The Impact of Left Main Disease on Long-term Clinical Outcomes Among Patients Treated With The Unrestricted Use of Everolimus-Eluting, Sirolimus-Eluting, and Paclitaxel-Eluting...

Presenter: Aris Moschovitis, Giulio Stefanini, Michael Magro, Lorenz R?ber, Bindu Kalesan, Masanori Taniwaki, Joost Daemen, Peter Wenaweser, Ron Van Domburg, Bernhard Meier, Peter Juni, Patrick Serruys, Stephan Windecker

January 31, 2013

Presentation TCT 2013

Impact of Varying Injury Severity and Multiple Treatments on Arterial Histopathology Early After Paclitaxel Coated Balloon Treatment of the Iliofemoral Arteries of Domestic Swine

Presenter: Maxwell Afari, Armando Tellez, Seung-Jin Oh, Krzysztof Milewski, Piotr Buszman, Renu Virmani, Juan Granada, Greg Kaluza

January 31, 2013

Presentation TCT 2013

Everolimus Eluting Stents Versus First Generation Drug Eluting Stents (Sirolimus or Paclitaxel) for Treatment of Drug-Eluting Stent In-Stent Restenosis

Presenter: Sachin Goel, Wael El-Mallah, Mobolaji Ige, Supriya Gupta, E Murat Tuzcu, Stephen Ellis, Samir Kapadia

January 31, 2013

Advertisement

Detection of Paclitaxel Contamination Resulting from the Simulated Clinical Use of Drug Coated Balloon Catheters

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

TCT 267: Lower Mortality of Paclitaxel-Coated Balloon Compared with Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis: Two-Year Follow-up of the PEPCAD China ISR Trial

PEPCAD-DES at 3 Years: Paclitaxel-Coated Balloon Holds Advantage for DES Restenosis

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

Vascular Healing in the Setting of Drug Deposition via Paclitaxel-Coated Balloon Delivery: Biological Implications for Device Development

Drug-coated Balloons May Become Standard of Care in ISR

LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries

RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

LEVANT 2, RIBS Show Promise for Paclitaxel-Coated Balloons in PAD and CAD

TCT-38. Three-year clinical data of the BIOSOLVE-I Study with the paclitaxel-eluting bioabsorbable magnesium scaffold (DREAMS) and multi-modality imaging analysis

TCT-13. Final Five Year Results From The All-comer COMPARE Trial: A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

TCT-56. PEPCAD China ISR: A Prospective, Multicenter, Randomized Trial of Paclitaxel-Coated Balloon versus Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis ...

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

PATENT-C: A Prospective, Randomized Trial of a Paclitaxel-Coated Scoring Balloon vs. a Standard Balloon for Treatment of Coronary In-Stent Restenosis

A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon Plus Bare Metal Stents vs. Paclitaxel-Eluting Stents for De Novo Coronary Lesions

Update on the DREAMS Paclitaxel-eluting and Sirolimus-eluting Magnesium Scaffolds: Device Design, Elution Kinetics, Imaging and Extended Clinical Results

The Impact of Left Main Disease on Long-term Clinical Outcomes Among Patients Treated With The Unrestricted Use of Everolimus-Eluting, Sirolimus-Eluting, and Paclitaxel-Eluting...

Impact of Varying Injury Severity and Multiple Treatments on Arterial Histopathology Early After Paclitaxel Coated Balloon Treatment of the Iliofemoral Arteries of Domestic Swine

Everolimus Eluting Stents Versus First Generation Drug Eluting Stents (Sirolimus or Paclitaxel) for Treatment of Drug-Eluting Stent In-Stent Restenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content